Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 20/20 | 0.98 |
| ▸ | ADRA1D | P25100 | 18/20 | 0.98 |
| ▸ | ADRA1B | P35368 | 18/20 | 0.98 |
| ▸ | ADRA2A | P08913 | 16/20 | 0.98 |
| ▸ | ADRA2B | P18089 | 16/20 | 0.98 |
| ▸ | ADRA2C | P18825 | 16/20 | 0.98 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5919546 | 1.00 | ADRA1A (0.98) | ADRA1AADRA1DADRA1BADRA2AADRA2B | |
| Hydrochloric Acid SCHEMBL7033291 | 0.98 | ADRA1A (0.98) | ADRA1AADRA1DADRA1BADRA2AADRA2B | |
| SCHEMBL5452997 | 0.93 | ADRA1A (0.89) | ADRA1AADRA1DADRA1BADRA2AADRA2B | |
| SCHEMBL5453007 | 0.93 | ADRA1A (0.89) | ADRA1AADRA1DADRA1BADRA2AADRA2B | |
| SCHEMBL7237529 | 0.89 | ADRA1A (1.00) | ADRA1AADRA1DADRA1BADRA2AADRA2B | |
| Hydrochloric Acid SCHEMBL8537000 | 0.88 | ADRA1A (0.98) | ADRA1AADRA1DADRA1BADRA2AADRA2B | |
| SCHEMBL7029472 | 0.85 | ADRA1A (0.75) | ADRA1AADRA1DADRA1BADRA2AADRA2B | |
| SCHEMBL7237578 | 0.84 | ADRA1A (0.74) | ADRA1AADRA1DADRA1BADRA2AADRA2B | |
| Hydrochloric Acid SCHEMBL7236187 | 0.81 | ADRA1A (0.73) | ADRA1AADRA1DADRA1BADRA2AADRA2B | |
| Hydrochloric Acid SCHEMBL7240209 | 0.81 | ADRA1A (0.85) | ADRA1AADRA1DADRA1BADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050101607-A1 | Pharmaceutical composition containing a beta-3-adrenoceptor agonist and an alpha antagonist and/or a 5-alpha reductase inhibitor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-05-12 | — | — | US | claimed |
| EP-1804778-A1 | USE OF A BETA-3 AGONIST FOR TREATING COMPLAINTS OF THE PROSTATE AND THE LOWER UROGENITAL TRACT | Boehringer Ingelheim International GmbH (DE) | 2007-07-11 | — | — | EP | disclosed |
| EP-1769792-A1 | Use of a beta-3 adrenoceptor agonist for the treatment of renal and bladder problems | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2007-04-04 | — | — | EP | disclosed |
| WO-2006042679-A1 | USE OF A BETA-3 AGONIST FOR TREATING COMPLAINTS OF THE PROSTATE AND THE LOWER UROGENITAL TRACT | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-04-27 | — | — | WO | disclosed |
| US-20060084700-A1 | Use of a beta-3 agonist for the treatment of disorders of the prostate and of the lower urogenital tract | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-04-20 | — | — | US | disclosed |
| US-20050101607-A1 | Pharmaceutical composition containing a beta-3-adrenoceptor agonist and an alpha antagonist and/or a 5-alpha reductase inhibitor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-05-12 | — | — | US | disclosed |
| US-20040072851-A1 | Medicinal compositions for treating lower uropathy | ASTELLAS PHARMA INC. (JP) | 2004-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101607-A1 | Pharmaceutical composition containing a beta-3-adrenoceptor agonist and an alpha antagonist and/or a 5-alpha reductase inhibitor | ADRB1, ADRB3, ADRB2 | ADRA1A 6/4885ADRA1D 7/4885ADRA1B 4/4885 |
| US-20060084700-A1 | Use of a beta-3 agonist for the treatment of disorders of the prostate and of the lower urogenital tract | ADRB3, ADRB2, ADRB1 | ADRA1A 9/4885ADRA1D 10/4885ADRA1B 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.